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Age-related muscle wasting and increased frailty are major socioeconomic as well as medical problems. In the quest to extend
qualityoflifeitisimportanttoincreasethestrengthofelderlypeoplesuﬃcientlysotheycancarryouteverydaytasksandtoprevent
them falling and breaking bones that are brittle due to osteoporosis. Muscles generate the mechanical strain that contributes to the
maintenanceofothermusculoskeletaltissues,andaviciouscircleisestablishedasmusclelossresultsinbonelossandweakeningof
tendons. Molecular and proteomic approaches now provide strategies for preventing age-related muscle wasting. Here, attention
is paid to the role of the GH/IGF-1 axis and the special role of the IGFI-Ec (mechano growth factor/MGF) which is derived from
the IGF-I gene by alternative splicing. During aging MGF levels decline but when administered MGF activates the muscle satellite
(stem) cells that “kick start” local muscle repair and induces hypertrophy.
1.Introduction
When our hominid species evolved from several millions
of years ago, ancient man was a hunter-gatherer, and
survival required covering long distances. As well as stamina,
homosapiens had to have suﬃcient strength to kill large
animals for food. Ancient man would have sustained muscle
injuries during hunting and tribal confrontations, and, from
aDarwinianviewpoint,naturalselectionwouldhaveresulted
in generations of oﬀspring with strong and adaptable
musculature; this includes rapid and eﬀective tissue repair as
this was also a requisite for survival and the continuation of
the species. However, over most of this time the average life
expectancy for most homosapiens was only about 25 years,
that is to say a little beyond the age of reproduction. For
example, in ancient Egypt the average life span was 24 years
but now with developments in science and medicine this has
increased by over 3-fold which presents problems for human
society. In the more aﬄuence society of today there are
other factors such as overconsumption of food and alcohol
and the failure to maintain an active, healthy life style. In
Scandinavian countries family doctors prescribe exercise to
improve the general ﬁtness which enables individuals to
maintain an active life style and to live longer. Longevity
and the increasing percentage of elderly in the populations
in many developed countries including the USA, Europe,
and Japan present its own major socioeconomic as well as
medicalcareproblems.Thereforemaintainingindependence
has now to be very much focused on the aging processes of
the musculoskeletal system.
Mechanicaltissuesaredesignedtorespondtomechanical
forces, and it is important to determine why there is a
decreasing sensitivity of the transduction of mechanical
signals that maintain muscles and to what extent this is
due to inactivity or intrinsic tissue changes as we get older.
These are not simple questions to answer as such factors
as neurological input, blood ﬂow, and fatigue resistance
that include tissues other than muscle may become limiting
factors. From the prospective of the author the information
in this paper concentrates on that acquired over the last
decade on changes at the cellular and molecular levels
in aging muscle tissue as present day molecular genetics
and proteomics methods have provided us with tools for
studying the age-related muscle growth, adaptation, and
repair. Sarcopenia is the term that is often used to describe
the syndrome of age-related muscle loss which is somewhat
unfortunate as this implies that it is a disease rather than an
attenuation of processes that develop and maintain muscle2 Journal of Aging Research
in young healthy people. Postnatal growth of muscle is very
much inﬂuenced by hormones which include growth factors
and androgens, the circulating levels of which decrease with
age. This decrease in hormone levels in the elderly has
sometimes been referred to as the “somatopause” as this
occurs in males and females. Supplementing the levels of
thesehormoneshasbeenfoundtobebeneﬁcial,forexample,
oestrogen and progesterone replacement therapy in women
andadministrationoftestosteroneinelderlymentoimprove
muscle strength.
The insulin-like growth factor (IGF-I) system is begin-
ning to receive considerable attention as it is involved in
tissue growth, maintenance, and repair. Interestingly, an IGF
gene is present in invertebrate animals. This and its receptor
gene have been studied in the nematode worm C. elegans [1]
as it is involved in determining the life span of the worm by
suppressing cell death (apoptosis). Experiments have shown
that the IGF gene and its receptor gene represent a primitive
system involved in maintaining terminally diﬀerentiated
cells. In this way these determine lifespan in the nematode
worm [2] and have become a model for studying aging at the
very basic level. The lifespan of vertebrates including man is
of course much longer than the nematode worm. In higher
animals the IGF-I system is similar but more sophisticated
in that the family of genes and the alternate splicing of
genes in vertebrates result in a number of gene products.
In vertebrates during aging, muscles decline in strength
and adaptability [3]. Coincidentally, levels of insulin-like
factors decline. These are controlled by growth hormone
(GH) produced by the pituitary gland and referred to as
the GH/IGF-I axis which controls body mass particularly
muscle mass. However, space does not permit a discussion
of the combined eﬀects of growth hormone and androgens
on muscle during aging although this topic is still receiving
much attention and not reviewed here except where they
might be involved in GH/IGF-I axis [4].
However, this paper will concentrate mainly on the
adaptation mechanism(s) that are linked to the repair
processesviawhichmyoﬁbersadaptand/orarerepairedafter
being subjected to mechanical strain. As skeletal muscle is
a “postmitotic tissue” and cell replacement is not a means
of repairing damage as it is in most tissues and there has to
be a somewhat diﬀerent but eﬀective mechanism, otherwise
the cellular units would undergo cell death and not be
r e p l a c e d .T h i sd o e sh a p p e nt os o m ee x t e n ti na d v a n c e do l d
age when the maintenance and reinnervation of the muscle
ﬁbers begins to fail. In normal muscle events associated with
local damage and repair result in adaptation whereby the
muscles increase in strength but this decreases with age. In
diseasessuchasthemusculardystrophiesmusclerepairisnot
initiated in the normal way as certain cytoskeletal assemblies
are defective or missing as in Duchenne muscular dystrophy
that is the most severe type. In the mdx dystrophic mouse
that is an animal model for human Duchenne muscular
dystrophy, the muscles are unable to respond to mechanical
stimuli by initiating the repair signalling including splic-
ing the IGF-I gene towards the IGF-IEc. Because of the
original confusion of what was called IGF-IEb which has
almost the same sequence of IGF-IEc in the human and
because its expression increased in response to mechanical
signals, the latter was called mechano growth factor (MGF)
[5]. In experiments in which the dystrophin complex has
been restored by cell transfer, the appropriate signalling
including the production of MGF is restored [6]. During
normal ageing this mechanotransduction system apparently
becomes increasingly less sensitive as the ﬁbers become less
compliance due to increased amount and stiﬀness of the
ﬁbrous connective tissue in the muscles. In addition to
muscle stiﬀness, another factor is the drop in circulating
levels of some hormones which inﬂuence the expression of
the genes that result in the local signals that are produced
in response to physical activity. Studies of cellular changes
associated with age-related muscle atrophy indicated that
there is a considerable loss of muscle ﬁbers, motoneurons,
andmotorunits[7].Inamorerecentprojectstudiedinolder
men aged just over 70, with a follow-up study on the cohort
when they approached 80 years of age, the muscle cross-
sectional area and speciﬁc strength of the knee extensors
had signiﬁcant decreased [8]. Interestingly, there was some
increase in the size of the type IIA ﬁbers indicating that the
recruitment pattern of the myoﬁber types changed, and this
tended to compensate for the loss of fatigue resistance and
strength. This paper will, however, concentrate on molecular
biology and proteomic studies. By using these approaches
we can begin to understand the atrophy processes associated
with aging and the possibility of intervening in these
processes of loss of muscle mass and strength, as we age.
2. Approaches to TreatingAge-Related
Muscle Loss
2.1. Treating the Somatopause. One of the changes during
aging is that the circulating levels of GH drop markedly
with age and one approach to counteract the eﬀects of aging
might have been to administer human GH as a recombi-
nant peptide. In experiments with the author’s group in
collaboration with Professor Kjaer’s group in Copenhagen,
it was found that strength improved with the administration
of growth hormone which apparently increases the level of
the primary IGF-I transcript and there was a correlation
between increased MGF levels and muscle mass measured
by MRI scanning [9, 10]. More recently our group has
been involved in detecting the misuse of GH by athletes
but it should be appreciated that young healthy individuals
are not GH deﬁcient. Therefore, the response is likely to
be diﬀerent to that in older muscle tissue, particularly in
those individuals in whom the circulating levels are well
below that of their age group. A study by Yamaguchi et al.
[11] showed that in hypophysectomized rat muscle the
expression of IGF-I splice variants was more inﬂuenced by
mechanical factors than endocrine status. This reaﬃrmed
a earlier study carried out a good number of years ago
by Goldberg [12] who used hypophysectomized rats and
showed when muscles are under mechanical strain they
still underwent hypertrophy indicating that regulation of
muscle mass and strength are regulated at the muscle cellular
level.SystemicadministrationhasassociatedproblemsasGH
is produced episodically, and there is a negative feedbackJournal of Aging Research 3
so that administration of a large bolus of recombinant
human growth hormone (rhGH) shuts down its endogenous
secretionbythepituitarywhichproducestheoppositeresult.
Also elevated GH levels are associated with an increased
in IGF-I and increased cancer risk as IGF-I is carcinogenic
at abnormally high levels although it has been reported as
repressing protein breakdown [13]. A higher risk of cancer
is seen in acromegalic patients whose pituitary gland is
overactive. These people are invariably tall and well muscled
but have a high risk of cancer resulting from the higher
circulating levels IGF-1. It is now becoming apparent that
this may be a problem in young athletes and bodybuilders
and the antidoping agencies are becoming concerned about
this form of abuse. Hence there are considerable risks
associated with elevating the serum GH levels beyond that
which is normal for a particular age group artiﬁcial elevation
of GH or IGF. The levels of several hormones are known to
drop markedly with age including testosterone as well as GH
that are involved in the maintenance of muscle mass. It is
not likely that these would be used as a general treatment for
age-relatedmusclelossalthoughitmaybeindicatedforsome
elderly individuals but this has to be combined with exercise
to obtain an increase in strength [10]. As the endocrine
system is complex and the chances of inducing unwanted
side eﬀects are reasons why the pharmaceutical industry is
attempting to develop SARMS, these compounds stimulate
speciﬁc androgen receptors, in particular the testosterone
receptor, and already they have found their way into doping
in certain sporting events.
2.2. Manipulation of the Balance between Protein Synthe-
sis/Breakdown. The size of tissues in the body is determined
mainly by a balance between the rate at which proteins are
synthesised and the rate they are broken down. This is a way
cells adapt to change in local environmental conditions and
for removing nonfunctional, damaged proteins. Every few
days approximately half the enzyme molecules within our
body will be broken down and replaced. The turnover of the
contractile proteins of muscle such as actin and myosin takes
a little longer with about half of being replaced every two
weeks or so.
Using nonradioactive isotope methods it was found that
as we get older our muscle proteins are degraded and
r e b u i l ta tl e s sf r e q u e n ti n t e r v a l sb u ts t i l lt h ep r o c e s si sv e r y
dynamic. Protein degradation requires energy as does the
synthesis of muscle proteins, and it appears that the balance
is more towards decreased protein synthesis except in some
disease states, for example, endotoxin poisoning, in which
muscle protein breakdown can be very rapid. Any proposal
for increasing muscle mass during aging by slowing the
degradation process during healthy aging would seem to be
physiologically undesirable as continual replacement of pro-
teins is particularly important in a mechanical tissue as this
is the way of ensuring there is no build-up of nonfunctional
proteins. Also in tissues such as muscle there would probably
be a reduction in speciﬁc strength as increased mass does
not necessarily mean an increased ability to generate muscle
force, and there is no rationale for increasing body mass
without commensurate increases in strength.
2.3. Blocking Negative Regulation of Muscle Mass. There has
been a lot of interest in a negative muscle regulatory factor
that has been named myostatin. As the name implies this
factor reduces muscle growth, and knocking this out ther-
apeutically oﬀered prospects of increasing muscle mass and
strength. The myostatin gene, when mutated, is responsible
for “double muscling” in certain breeds of cattle, such as
the Belgian Blue, which exhibit very considerable muscle
hypertrophy [14] and also in a few human subjects in which
the gene is mutated [15]. However, McMahon et al. [16]
reported that in the myostatin knockout mouse, the lack of
myostatin did not ameliorate disuse atrophy. As discussed
below skeletal muscle is a postmitotic tissue and in order
to increase in size or to repair the myoﬁbers have to obtain
extra nuclei. Postnatal inactivation of the myostatin by gene
targeting results in myostatin “knock out” with an increased
number of satellite cells [17], and an increase in muscle
mass reverses the quiescence state of these muscle progenitor
cells [18]. However, it was shown in these mice [19] that
the increased muscle mass resulted in decreased speciﬁc
contractile force as there was apparently an accumulation of
nonfunctionalprotein.Thesuggestedtherapyformuscleloss
that entails partially knocking out/knocking down myostatin
is also probably not a good strategy as this is associated with
al o s so fo x i d a t i v ec a p a c i t yo ft h em u s c l e sa sw e l la si m p a i r e d
respiratory and cardiovascular function [20]. In one young
boy who has a myostatin double allele knockout, he has
increasedmusclemassandstrengthandthiswouldobviously
be an advantage in certain sports, but to be “muscle bound”
is not necessarily an advantage in many activities that require
power rather than maximum force nor would it be desirable
for older people. Interestingly, a study on aging weight lifters
did show that myostatin levels decrease when they resume
exercise so this subject needs further investigation. Clearly
if the use of an antimyostatin strategy results in an increase
of mass without a commensurate increase in strength this
would handicap rather than help elderly individuals.
2.4. Augmenting the GH/IGF-I System for Maintaining Muscle
Mass and Strength. Even in individuals who exercise reg-
ularly, the ability to maintain muscle mass and strength
diminishes with age, and this is associated with the marked
drop in the circulating serum levels of IGF-I. Muscle
hypertrophy and wasting have been studied at the gene level
based on the realisation that there must be local as well
as systemic regulators of muscle growth. Approximately 15
years ago the author’s group cloned a factor that proved to
be involved in local regulation of muscle mass and which is
derived from the splicing of the IGF-I gene. To do this we
used an animal model in which we could make muscle grow
rapidly. Previous work had shown that the tibialis anterior
in the mature rabbit whilst held in the stretched position
by a plaster cast and when electrically stimulated using an
implantedmicrocircuitincreasedinmassby35%injustover
7d a y s[ 21]. It was known that muscles adapt to an increased
functional length by adding sarcomeres in series at the ends
of the existing myoﬁbrils, and if they are also subjected to
electrical stimulation they also increased in girth and also
added more sarcomeres in parallel as well as in series. RNA4 Journal of Aging Research
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Figure 1: Schematic representation of the splicing of the human IGF-I gene in human muscle to produce human MGF (IGF-1Ec) as well
as IGF-IEa and IGF-IEb. The IGF-I gene has two start sites located in or near exons 1 and 2. In response to a exercise/damage the IGF-I
gene is ﬁrst spliced to produce MGF. This involves a reading frame shift that results in the unique carboxy terminal sequence (E domain)
of MGF (IGF-I Ec). The expression of the IGF-I gene is initiated by certain hormones, and this becomes a problem as during aging GH
and testosterone levels decrease resulting in decreasing levels of the primary transcript so less can be spliced to MGF when the muscle is
mechanically challenged. Also it appears that the mechanotransduction and signalling system that is upstream of the activation of the IGF-I
gene also become less sensitive, and less MGF is produced.
wasextractedfromthesemusclesthatwereundergoingrapid
growth and using diﬀerential display, and we detected a RNA
transcript that is expressed in stretched/exercised but not
in resting muscles. This mRNA was converted to cDNA,
sequenced, and referred to the genome data base which
showed it to be derived from the insulin-like growth factor
(IGF-I) gene. However, its 3  sequence was diﬀerent to the
liver or systemic type of IGF-I (IGF-IEa) [22].
Later work showed that in human muscle 3 main types
of IGF-I can be spliced from the IGF-I gene (Figure 1), a
systemic (liver) type of IGF-I (IGF-IEa), IGF-I Eb, that is
not the same as IGF-IEb in rodents and the newly discovered
splice variant IGF-IEc. As the terminology of the IGF-Is is a
problem when attempting to apply it to nonhepatic tissues
and diﬀerent species we called this newly discovered splice
variant mechano growth factor (MGF) as it is expressed in
response to mechanical stimuli and muscle damage.
As well as MGF expression was mechano sensitive its 3 
sequencewasuniqueandencodedadiﬀerentEdomainatthe
carboxy end (Figure 1) that presumably has several distinct
actions. The reason the C terminal end of MGF is diﬀerent to
the other IGF-I splice variants is because during the splicing
of the IGF-I gene at exon 5 has 52 bases in the human (49
bases in rabbit and rat) and this introduces “a reading frame
shift” at the 3  end. Following the initial splicing to MGF
(human IGF-IEc) which has been found to initiate muscle
growthandrepair,theIGF-IgeneislaterswitchedtoIGF-IEa
which is a main anabolic agent and some studies suggest that
it initiates the fusion of satellite cells with the myoﬁbers and
the expression of myogenic genes [22–24]. MGF, however,
a p p e a r st oh a v eas p e c i a lr o l ei nm u s c l er e p a i rt h a ti n v o l v e s
its unique E domain sequence that arises from this reading
frame shift [25]. As well as activating and replenishing the
muscle stem/precursor cell pool (see Figure 1) this unique
E domain peptide has also been found to have several roles
in limiting tissue damage but space does not permit these
to be reviewed here. There is good evidence that the age-
related changes in muscle mass and strength result from a
decreasing ability to produce MGF [26–28], and this seems
likely to be the case in other tissues. From a physiological
point of view this is interesting as the age-related decline in
theabilitytorespondtophysicalsignalsbyproducingMGFis
presumably related to a dulling of the mechanotransduction
system which is still not understood.
2.5. Exercise and Decreasing Ability to Respond to Active
Muscle Stretch during Aging. As shown in the rat (Figure 2)
and human subjects a major intrinsic eﬀect is increased
load, but this response becomes dulled during aging [26].
Also in studies on elderly human subjects [27] this wasJournal of Aging Research 5
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Figure 2: The ability to express MGF in response to mechanical
strain with age. Animal experiments overloading the rat soleus
and plantaris muscles by cutting the gastrocnemius muscle of
rats from 3 age groups. In the young rat the overloaded muscles
produced high levels of MGF but in the older rats the induced
levels were much lower even though these rats were much heavier.
The middle-age rats the MGF levels were intermediate between the
young and the old in response to mechanical overload, according to
Owino et al. [27].
found to be related to decreased MGF and IGF-1Ea which
could be improved by administration of GH which increases
the expression of the IGF-I gene. (see Figures 3(a)–3(c)).
As mentioned above in Section 2.4 we understand more
about the endocrine aspects than the physical signalling and
signalling molecules involved in muscle adaptation involved
in maintaining and repairing our muscles as we age.
The detection of mechanical strain is thought to involve
focal adhesion kinases (FAKs) [30] which are activated by
mechanotransducers systems that link the very long titin
molecules that run through the myoﬁbrils to the tendons.
Thesealsoconnectin3dimensionsasthemyoﬁbrillarsystem
is linked to the surrounding basal lamina and response ele-
ments, and when these are missing, for example, dystrophin
or defective is responsible for the muscle wasting conditions.
The connective tissue of the tendons and ligaments also
transmits the forces generated by sarcomeres of the muscles
to tendons, bones, and ligaments. These mechanical forces
generated by skeletal musculature are thus also involved
in maintaining the whole of the musculoskeletal system.
It seems that as we grow older this mechanotransduction
system becomes less sensitive because of the decreased
compliance of the connective tissue due to cross-linking of
the collagen which seems to occur in all tissues. In some
experiments on mice subjected to repeated exercise the
author’s group found that regular exercise improved muscle
compliance during aging but it was still not as good as in
young mouse muscles [30]. These experiments preceded the
discoveryofMGFwhichnowoﬀersgoodprospectsforitsuse
as a therapeutic compound for treating age-related muscle
loss as well as muscle cachexia in a range of diseases although
there seems to be more interest in its use as a doping agent as
it is available over the internet and it is now being produced
using recombinant E. coli methods, and therefore it will
become relatively inexpensive. Unfortunately, during aging
the muscles become less compliant and become less able to
produce MGF [26–28, 31]. As with other tissues muscles
become less compliant which apparently occurs due to cross-
linking in the connective tissues and possibly other factors,
and in some long running mouse experiments we showed
that regular exercise improved muscle compliance during
aging but it was still not as good as in young mouse muscles
[30]. Also in diseases such as the muscular dystrophies, the
impairment is often the absence or incorrect conformation
of the certain linking molecules such as dystrophin that
apparently results from an inability to produce MGF. From
a physiological point of view this is of considerable interest
as the initiation of the activation of the IGF-I gene and the
switch in splicing to produce MGF must involve a mechan-
otransduction system. The detection of mechanical strain
is thought to involve focal adhesion kinases (FAKs) which
change conformation when stretched which phosphorylate
other signal molecules [32]. The impairment of mechanosig-
nalling appears to be defective in diseases such as the
muscular dystrophies in which splicing of the IGF-I gene is
deﬁcient but transfer of normal mesenchymal stem cells into
the dystrophic mouse restored its ability to produce MGF
[33]. Therefore, there are probably good prospects for use of
therapeuticcompounds suchasMGFfortreating age-related
muscle loss as well as muscle cachexia in a range of diseases.
Unfortunately, at the present there seems to be more interest
in its use as a doping agent as it is available over the internet
and it is now being produced using recombinant E. coli
methods, and therefore it can become relatively inexpensive.
2.6. Muscle Progenitor/Satellite Cells in Muscle Repair, Adap-
tation, and Maintenance. Skeletal muscle and most neu-
rological tissues are postmitotic tissues, and age-related
deﬁcits require a somewhat diﬀerent understanding to that
of other tissues. The term “postmitotic tissue” is used as after
embryonic tissue is complete, the myoﬁbers have residual
myoblasts in the space between the plasma membrane and
the basal lamina. Because of their position these mononu-
cleated cells were originally called satellite cells. These upon
the appropriate signal undergo proliferation and one of
the progeny fuses with the muscle ﬁbres, and the other
mononucleated muscle stem cell enters quiescence.
It has been realized for some time that these cells provide
the extra nuclei for postnatal growth and regeneration [32]
and in response to mechanical strain and local injury [32–
38].Growing upmononucleatedmyoblastsforinjection into
musclesofpatientshasbeenthegoalforseveralgroupsbutas
mostofthesedieafterinjection,thisdoesnotseempreferable
to introducing MGF as a stabilized peptide or gene construct6 Journal of Aging Research
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Figure 3: (a) Exercise data in which muscle MGF levels were determined in elderly men; some receiving exercise only and another group
exercise with GH and in which biopsies were taken and MGF levels were measured and compared with muscle cross-sectional area and
strength. (b) shows the relationship between the induced levels of MGF and the increased strength in the experiments presented in (a). (c)
presents on the left side the change in muscle cross-sectional area after exercise combined with GH treatment and increased MGF expression
in elderly men. On the right are two scans showing the diﬀerence when exercise is combined (top right) or not combined with GH treatment
(bottom left). See Hameed et al. [28].
as one injection provides many additional myoﬁber nuclei.
The initial splicing of the IGF-I gene to produce MGF is
within the ﬁrst few days after the mechanical challenge and
coincides with the activation of the muscle stem cell pool
[36–38]. Indeed, the initiation of muscle stem cells resulting
from exercise has been shown in human muscle after a single
bout [37]. Bamman’s group [38] found that after resistance
exercise there was a correlation between cyclin D1 activityJournal of Aging Research 7
with MGF expression demonstrating cell replication in this
postmitotic tissue. In another study it was shown that a
decrease in myostatin levels results in an increase in speciﬁc
strength so it is assumed that muscle satellite (stem) cell
activation is positively regulated by MGF and not by removal
of myostatin, the negative regulator [18]. Following the
expression of the IGF-I gene the satellite cell pool undergoes
periods of replenishment lasting just a few days [34], and
theinitialsplicingtoMGFexpressionfollowingamechanical
challenge ﬁts with the timing of the expansion of the muscle
stem(satellite)numbers[30,39].BothMGFandIGF-IEaare
apparently involved during muscle hypertrophy and repair
as this involves replenishing the muscle satellite (stem) cell
pool which “kick starts” the growth, and repair processes the
anabolic response to IGF-I Ea. Stem cell therapy has been
proposed for extending the life and the quality of life but
in the case of muscle loss and frailty and in muscle cachexia
in a range of diseases. However, transplanting muscle cells
would not seem to be necessary if the existing stem cells can
be induced to multiply by merely administering MGF as a
stabilised peptide or by gene therapy.
2.7. Activation of Muscle Progenitor Cells in Muscle Wasting
a n dd u r i n gA g i n g .It has been shown that age-related sar-
copeniaisrelatedtoIGF-Isignaling[34,35]andinparticular
reduced ability of muscle to express MGF, a splice variant of
the IGF-I gene and also IGF-IEa which is the main anabolic
agent or increased muscle protein content [34, 36]. This
has been associated with muscle aging in animals [22, 26]
and humans [27, 28], and because of this, the need to
activate the muscle stem/progenitor cells to increase muscle
mass has been highlighted in a number of publications [35–
41]. For this purpose the unique E peptide sequence of
MGF (MGF-24aa-E) was used to study the activation of
the human satellite cells (mononucleated myoblasts) taken
from patients with muscle wasting diseases including two
muscular dystrophies and ALS [41]. If IGF-I was added
together with the MGF peptide then it became apparent
that the mononucleated cells went through the next stage
of activation and fused with the muscle myoﬁbers in the
cultures. Therefore, it seems that both the unique MGF E
domainpeptideandIGF-Iarerequiredfortherepairprocess.
Work withDr. Gillian Butler-Browne’s group [42] shed more
light on the repair process in relation to aging. With this
group we investigated the actions of the MGF E-24aa peptide
using diﬀerentiated cultures and analyzed to estimate (1)
the fusion index, (2) the percentage of unfused (desmin
positive) reserve cells, and (3) the mean number of nuclei
permyotube.Afusionindexwasdeterminedbycountingthe
number of nuclei in the diﬀerentiated myotubes with more
than two myonuclei as a percentage of the total number of
nuclei (mononucleated and multinucleated). The percentage
of unfused positive cells was calculated, by counting the
number of unfused, desmin-positive-single-nucleus cells as
a percentage of the total number of nuclei (1000 nuclei
per dish in triplicate). To measure the extent of cellular
proliferationwithinaculture,theincorporationof5-bromo-
2 -deoxyuridine (BrdU) was used. During the replicative
life span, proliferating cells were incubated for 72h in the
presence of 10µg/mL of BrdU. To identify the cells that had
incorporated BrdU, using a monoclonal antibody directed
against BrdU, and the nuclei were counterstained with DAPI.
ItwasfoundthatthisMGFpeptidesigniﬁcantlyincreasesthe
proliferative life span of satellite cells isolated from neonatal
and young adult but not from old adult muscle. However,
it was noted that the mean number of nuclei per myotube
and the fusion index were higher in cultures from older
subjects. Interestingly, hypertrophy was observed in satellite
cell cultures from all three age groups. This was associated
with a signiﬁcant decrease in the percentage of “reserve”
cells correlated with an increase in the number of nuclei in
the myotubes that occurred when MGF-24aa-E peptide was
added to cultures. It is concluded that only 24aa of the MGF
isoform of IGF-1 has a marked ability to initiate and enhance
satellite (progenitor) cell replication and fusion for muscle
repair and maintenance. Aging muscle has a declining ability
to produce MGF but it was found that administration of
the MGF peptide prevents satellite cells entering senescent
and by activating these reserve progenitor cells to fuse,
and this provides the extra nuclei required for continued
tissue maintenance. Unfortunately as mentioned above as
we become older our ability to produce MGF declines along
with GH and IGF-I. Although the older myoblasts cultures
showed a dramatic decrease in the number of cycling cells
followingtheadditionofMGF-24aa-E,theirabilitytoinduce
hypertrophy was assessed following a single dose of MGF-
24aa-E which was given immediately or just after 3 days
of establishing which resulted in the cultures developing
myoﬁbers and producing additional myosin heavy chain
protein [42]. Also it appears that MGF-24aa-E signiﬁcantly
delays the entry of cells into senescence and increases
moderately the proliferative life span of satellite cells isolated
from neonatal and young but not from old adult skeletal
muscle. These experiments allow the distinction between
two speciﬁc roles of MGF E-24aa peptide and its eﬀects on
proliferation and diﬀerentiation that are required for the
maintenance and then repair of the musculature throughout
life (see Figures 4 and 5).
3. Conclusions
It has been known for some time that during aging there is
a marked decline in muscle mass and strength which can be
only partly ameliorated by continuing with resistance type
of training. Exercise is to be encouraged as it has health
beneﬁts and a feeling of well-being during the aging process.
However, in old age many individuals will become partially
or only partially immobile. In the aging population day- to-
day care will increase as a percentage of the elderly, and this
will result in an ever-increasing ﬁnancial commitment par-
ticularly in the advanced nations. For this and other reasons
the large pharmaceutical companies have recently taken a
serious interest in possible ways to increase muscle mass and
strength in the elderly and in the many disease states that are
accompanied by muscle loss. Much of their recent research is
kept conﬁdential for obvious reasons but can be appreciated
somewhat from ﬁled patents some of which had been ﬁled
by academic institutions before the present ﬁnancial crisis.8 Journal of Aging Research
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Figure 4: Illustrates role of the MGF C terminal peptide in activating the replication of the mononucleated myoblasts (otherwise termed as
satellitecellsormuscleprogenitor/stemcells).Thesearethesourceoftheextranucleirequiredforlocalmusclerepair.MGFinyoungnormal
muscle replenishes the pool of stem cells, and myostatin acts as a negative regulator and pushes then into a quiescent mode. Following the
activation of the mononucleated myoblasts to undergo mitosis one of the pair will fuse with the myoﬁber and switch into myogenic gene
expression for the production of contractile such as actin and myosin and other muscle proteins.
However, it seems that in the reasonably near future, when
we understand better the signaling and the role of IGF-I
growth factors, it should be possible to strengthen the mus-
culature in the inﬁrm so they can continue to carry out rou-
tine physical tasks. It has been known for some time that GH
levels markedly decrease during aging and GH supplementa-
tion increases muscle mass in the elderly [28]. Serum IGF-I
levels also decrease during aging but administration of IGF-I
isproblematicbecauseofitsinsulin-likeeﬀectonbloodsugar
levels, and the main consensus in a point:counterpoint dis-
cussion was that IGF is not a major regulator of muscle mass
[43]. Over the past decade or so, studies have demonstrated
alternative splicing events occur in the IGF-1 gene in skeletal
muscle in response to mechanical strain. This splicing results
in the production of diﬀerent 3  mRNA and a diﬀerent
terminal amino acid sequence in main splice variants and
isoforms. Initially there was confusion as the splice variants
previously named IGF-IEb in the rat but IGF-IEc in the
human are essentially the same although shift in the reading
frame shift occurs at a slightly diﬀerent place and the C
terminal peptides (E domain) have just a few amino acids
diﬀerence. In animals and humans this unique E domain has
special functions. Because of this confusion the IGF-I splice
variants were named mechano growth factor (MGF) as the
splicing of the IGF-I gene responses to mechanical signals
[21–28]. Experiments using a synthetic peptide of just 24
amino acids increased murine myoblast C2C12 cell cultures,
and using myoblasts transfected with MGF cDNA showed
proliferation in these mouse muscle cell cultures [24]. Some
groups found the experiments with the E peptide diﬃcult
to repeat as unfortunately they used commercially available
murine C2C12 cells which had been grown up so many
times and very few, if any of these transformed and mutated
cells behaved as muscle progenitor cells. Heinemeier et al.
cloned the few progenitor cells by separating them from the
transformed cells that continually multiplied whether or not
they were exposed to MGF or IGF-I [44]. There was a lesson
to be learnt from this, and the author’s group concentrated
on using human muscle mononucleated myoblasts obtained
bybiopsiesfrompatientswithmusclewastingdiseases.Itwas
that a 24h treatment with this peptide increased the number
ofprogenitorcellsobservedinprimaryculturesfromhealthy,
ALS,anddystrophichumancellsinvitro[41].Asfarasaging
is concerned our studies have shown that older muscles are
less able to produce MGF, and this seemingly results in an
age-related loss in both muscle mass and strength. Recent
studies by Gillian Butler-Browne’s group in Paris and our
group in London who used primary cultures found that
human mononucleated/desmin-expressing myoblasts [42]
from young muscle biopsies reacted somewhat diﬀerently to
those from elderly muscle when cultured. Muscle progenitor
cells like other diploid somatic cells have a ﬁnite potential
to divide before they become senescent but it was found
that the myoblasts from older individuals still responded to
the unique 24aa MGF peptide but in a somewhat diﬀerent
way. Treatment with the MGF-24aa-E peptide increased
the proliferative capacity of the human myoblasts isolated
from neonatal and young adult muscle. Those cultured
from old adult muscle showed a marked increase in nuclei
per myotube (see Figure 5). In the old muscle there areJournal of Aging Research 9
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Figure 5: In elderly muscle MGF treatment activates “resting” cells
to proliferate and fuse to donate nuclei. Cultures from neonatal,
young adult, and old adult muscle were treated with the unique
MGF peptide (MGF E) 24aa at a concentration of 100ng/mL at day
0o rd a y3o fd i ﬀerentiation. Immunoﬂuorescence was performed
on cultures with an antibody directed against Desmin (a marker of
progenitor cell status). In elderly muscle there are still some muscle
satellite/stem cells in a quiescent state but these are not normally
activated because older muscle does not normally produce much
MGF. However when the unique E peptide of the MGF was added
to cultures from elderly muscle these cells replicated. The prospects
of “awakening” of these resting progenitor cells appear to oﬀer a
means of enhancing muscle maintenance and repair in the elderly
oﬀers and in certain diseases such as muscular dystrophy and ALS
(Kandalla et al. [29]).
considerable numbers of quiescent “reserve” cells, and their
activation by the unique E domain peptide increased in the
number of nuclei in the myotubes. The primary action of
the MGF E-24aa peptide on elderly muscle was to push
reserve myoblasts through the next step of fusion to start the
hypertrophy process.
It seems that as we grow older the system becomes
less sensitive for detecting mechanical strain because of
the decreased compliance of the tissue due to cross-linking
in the connective tissues. There is some evidence that the
compliance of the muscle connective tissue is increased more
than in sedentary individuals and this helps to maintain
power output as well as fatigability. Recent research has
shown that there are mechanosensor molecules such as
focaladhesion kinasesystems.Thesesignalling moleculesare
wishbone in structure and open out when stretched. As their
name denotes these FAKs are believed to involve activation
of phosphatases which are possible part of the upstream
activation of the splicing of the IGF-I gene to produce MGF.
It has been shown that the signalling associated with MGF is
diﬀerent to other splice variants of the IGF-I gene from the
humanexercisestudiescarriedoutatMcMasterUniversityin
Canada. The temporal response of MGF to acute damaging
exercise results in Myf5 and MyoD expression and the later
response to IGF-IEa and IGF-I Eb to MRF-4 to the acute
damaging repair phase [45] which occurs after the increase
in the number of extra nuclei triggered by MGF (human
IGF-1Ec). Confusion has arisen in this ﬁeld of study because
of the temptation to use murine myoblast cell lines such as
C2C12 cells. These transformed, mutated cells that readily
multiply are no longer suitable for this kind of study, and
this message has not yet been appreciated by pharmaceutical
companies or academic research groups.
The question remains, why does not exercise produce
as much MGF and the same muscle gain in the elderly as
in young individuals? We do need to understand the age-
related amelioration in the upstream signalling at the cellular
and molecular levels as this apparently holds the clues as to
why loss of muscle mass and strength and to put this in the
context of the musculoskeletal system as a whole. Eccentric
exercise has been found to be associated with Akt/mTor/p70
signalling [46] but we still do not know why there is no
apparentrelationshipinyoungindividualsandrateofstretch
in eccentric contractions, and at present this is presumed to
be the case in older individuals. Second messengers relating
to MGF expression have also been studied by the team in
the Bach Institute of the Russian Academy of Sciences, and
protein kinases A and C and cAMP appear to be involved
in MGF upregulation [47]a n dt h es p e c i ﬁ ct y p eo fe x e r c i s e
that should be more beneﬁcial for maintaining musculature
in the elderly [48]. MGF is expressed in other tissues
following mechanical strain and tissue damage [49]a n d
enhances myogenic precursor cell transplantation success
[50]. It is expressed in tendons following mechanical stress
and increased osteoblasts in bone after damage [44]. There
are also beneﬁcial eﬀects on the repair of the myocardium
[51–54]. MGF has been found to be very neuroprotective
[55], and this includes protection against oxygen-free radical
damage [53], and on this basis other aspects continuing to
exercise as we get older can be recommended. Therefore, it
seems that the splicing and expression of the IGF-I gene and
itsisoformsiscentraltoourunderstandingoftheprogressive
inability of tissue repair, and there are broader aspects then
just decline in skeletal muscle function [54, 56]. Although
the stabilized MGF E 244aa peptide can be purchased over
the internet it is expensive, and apart from research it is
apparently being used by body builders and doping for
improvedathleticperformance.Itispredictedthatitsusewill
bemorewidespreadasitcanbeproducedusingrecombinant
methods in the same way as human insulin. A group of Rus-
sian scientists [57, 58] are producing a MGF peptide in this
way and using it for bona ﬁde reasons that include alcoholic
myopathy and muscle atrophy resulting from space travel.
There is also much interest in China where recombinant
MGF is also being produced [59] but less is known about its
uses in these countries but it is clear that they appreciate its
potential for treating in tissue atrophy and repair.
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